Ciaran A Shaughnessy1, Pamela L Zeitlin2, Preston E Bratcher3. 1. Department of Pediatrics, National Jewish Health, Denver, CO. 2. Department of Pediatrics, National Jewish Health, Denver, CO; Department of Pediatrics, University of Colorado Denver, Anschutz Medical Center, Aurora, CO. 3. Department of Pediatrics, National Jewish Health, Denver, CO; Department of Pediatrics, University of Colorado Denver, Anschutz Medical Center, Aurora, CO. Electronic address: BratcherP@NJHealth.org.
Abstract
BACKGROUND: A decrease in the lumacaftor-mediated increase in F508del-CFTR function and expression upon prolonged exposure to ivacaftor (VX-770) has previously been described. However, the efficacy observed with ivacaftor-containing CFTR modulator therapies in vivo is in conflict with these reports. We hypothesized that a portion of the apparent decrease in CFTR function observed after prolonged ivacaftor exposure in vitro was due to an increase in constitutive CFTR-mediated ion transport. METHODS: Human nasal epithelial (HNE) cells were obtained by brushings from three CF individuals homozygous for the F508del CFTR mutation. Differentiated epithelia were pre-treated with prolonged (24 h) exposure to either lumacaftor (VX-809; 3 µM), tezacaftor (VX-661; 3 µM), elexacaftor (VX-445; 3 µM), and/or ivacaftor (0.1-6.4 µM) or DMSO (vehicle control), and CFTR function was assayed by Ussing chamber electrophysiology. RESULTS: In cells treated with lumacaftor, constitutive CFTR activity was not increased at any concentration of co-treatment with ivacaftor. Constitutive CFTR activity was also unchanged in cells treated with the combination of tezacaftor and elexacaftor. An increase in constitutive CFTR activity above the DMSO controls was only observed in cells treated with the combination of tezacaftor and elexacaftor and co-treated with at least 0.1 µM ivacaftor. CONCLUSIONS: These results demonstrate that ivacaftor is a critical component in the triple combination therapy along with tezacaftor and elexacaftor to increase constitutive CFTR function. This work further elucidates the mechanism of action of the effective triple combination therapeutic that is now the primary clinical tool in treating CF.
BACKGROUND: A decrease in the lumacaftor-mediated increase in F508del-CFTR function and expression upon prolonged exposure to ivacaftor (VX-770) has previously been described. However, the efficacy observed with ivacaftor-containing CFTR modulator therapies in vivo is in conflict with these reports. We hypothesized that a portion of the apparent decrease in CFTR function observed after prolonged ivacaftor exposure in vitro was due to an increase in constitutive CFTR-mediated ion transport. METHODS: Human nasal epithelial (HNE) cells were obtained by brushings from three CF individuals homozygous for the F508del CFTR mutation. Differentiated epithelia were pre-treated with prolonged (24 h) exposure to either lumacaftor (VX-809; 3 µM), tezacaftor (VX-661; 3 µM), elexacaftor (VX-445; 3 µM), and/or ivacaftor (0.1-6.4 µM) or DMSO (vehicle control), and CFTR function was assayed by Ussing chamber electrophysiology. RESULTS: In cells treated with lumacaftor, constitutive CFTR activity was not increased at any concentration of co-treatment with ivacaftor. Constitutive CFTR activity was also unchanged in cells treated with the combination of tezacaftor and elexacaftor. An increase in constitutive CFTR activity above the DMSO controls was only observed in cells treated with the combination of tezacaftor and elexacaftor and co-treated with at least 0.1 µM ivacaftor. CONCLUSIONS: These results demonstrate that ivacaftor is a critical component in the triple combination therapy along with tezacaftor and elexacaftor to increase constitutive CFTR function. This work further elucidates the mechanism of action of the effective triple combination therapeutic that is now the primary clinical tool in treating CF.
Authors: Radu G Avramescu; Yukari Kai; Haijin Xu; Aurélien Bidaud-Meynard; Andrea Schnúr; Saul Frenkiel; Elias Matouk; Guido Veit; Gergely L Lukacs Journal: Hum Mol Genet Date: 2017-12-15 Impact factor: 6.150
Authors: Elizabeth Matthes; Julie Goepp; Graeme W Carlile; Yishan Luo; Kurt Dejgaard; Arnaud Billet; Renaud Robert; David Y Thomas; John W Hanrahan Journal: Br J Pharmacol Date: 2016-01-13 Impact factor: 8.739
Authors: Puay-Wah Phuan; Guido Veit; Joseph A Tan; Walter E Finkbeiner; Gergely L Lukacs; A S Verkman Journal: Mol Pharmacol Date: 2015-08-05 Impact factor: 4.436
Authors: Dominic Keating; Gautham Marigowda; Lucy Burr; Cori Daines; Marcus A Mall; Edward F McKone; Bonnie W Ramsey; Steven M Rowe; Laura A Sass; Elizabeth Tullis; Charlotte M McKee; Samuel M Moskowitz; Sarah Robertson; Jessica Savage; Christopher Simard; Fredrick Van Goor; David Waltz; Fengjuan Xuan; Tim Young; Jennifer L Taylor-Cousar Journal: N Engl J Med Date: 2018-10-18 Impact factor: 91.245
Authors: Onofrio Laselva; Claire Bartlett; Tarini N A Gunawardena; Hong Ouyang; Paul D W Eckford; Theo J Moraes; Christine E Bear; Tanja Gonska Journal: Eur Respir J Date: 2021-06-17 Impact factor: 16.671